AngioDynamics Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de AngioDynamics de 76.3% y 4.4% respectivamente, mientras que el BPA crecerá en un 73.8% al año.

Información clave

76.3%

Tasa de crecimiento de los beneficios

73.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.5%
Tasa de crecimiento de los ingresos	4.4%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	05 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

Apr 09

AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry

Apr 06

AngioDynamics: Restructuring Initiative May Not Go Far Enough

Jan 14

AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Oct 12

AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt

Mar 31

AngioDynamics Non-GAAP EPS of -$0.06 misses by $0.04, revenue of $81.5M misses by $1.93M, reaffirms FY guidance

Oct 06

Shareholders May Not Be So Generous With AngioDynamics, Inc.'s (NASDAQ:ANGO) CEO Compensation And Here's Why

Oct 28

Is AngioDynamics (NASDAQ:ANGO) Weighed On By Its Debt Load?

Oct 07

AngioDynamics: Focusing On Three Credible Growth Drivers And Targeting Growth Acceleration

Jul 20

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:ANGO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
5/31/2026	314	-11	N/A	N/A	1
5/31/2025	287	-43	N/A	N/A	4
5/31/2024	287	-194	N/A	N/A	4
2/29/2024	324	-192	-23	-17	N/A
11/30/2023	330	-14	-7	-3	N/A
8/31/2023	336	6	-5	-1	N/A
5/31/2023	339	-52	-4	0	N/A
2/28/2023	335	-37	-12	-7	N/A
11/30/2022	328	-33	-22	-17	N/A
8/31/2022	321	-33	-28	-23	N/A
5/31/2022	316	-27	-11	-7	N/A
2/28/2022	306	-40	-7	-4	N/A
11/30/2021	303	-38	7	11	N/A
8/31/2021	298	-34	16	21	N/A
5/31/2021	291	-32	19	24	N/A
2/28/2021	273	-169	10	16	N/A
11/30/2020	271	-171	-14	-8	N/A
8/31/2020	268	-170	-21	-13	N/A
5/31/2020	264	-167	-22	-15	N/A
2/29/2020	277	-7	0	7	N/A
11/30/2019	273	-6	27	33	N/A
8/31/2019	273	-7	36	40	N/A
5/31/2019	271	-11	34	37	N/A
2/28/2019	205	-34	33	36	N/A
11/30/2018	223	-16	28	32	N/A
8/31/2018	240	-12	26	29	N/A
5/31/2018	262	-6	38	41	N/A
2/28/2018	343	1	33	37	N/A
11/30/2017	345	-10	N/A	47	N/A
8/31/2017	347	4	N/A	51	N/A
5/31/2017	270	-7	N/A	56	N/A
2/28/2017	356	-25	N/A	55	N/A
11/30/2016	358	-27	N/A	53	N/A
8/31/2016	357	-42	N/A	48	N/A
5/31/2016	351	-44	N/A	45	N/A
2/29/2016	347	-1	N/A	37	N/A
11/30/2015	346	-6	N/A	37	N/A
8/31/2015	349	-5	N/A	25	N/A
5/31/2015	352	-3	N/A	26	N/A
2/28/2015	356	-4	N/A	25	N/A
11/30/2014	358	5	N/A	12	N/A
8/31/2014	354	4	N/A	23	N/A
5/31/2014	351	2	N/A	25	N/A
2/28/2014	346	2	N/A	26	N/A
11/30/2013	340	-3	N/A	37	N/A
8/31/2013	340	0	N/A	40	N/A
5/31/2013	340	-1	N/A	27	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ANGO siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que ANGO siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que ANGO siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (4.4% al año) de ANGO crezcan más despacio que el mercado de US (8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 4.4% al año) de ANGO crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ANGO se prevé que sea elevada dentro de 3 años.

AngioDynamics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 10.0% to US$13.50

AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024

Angiodynamics, Inc. Provides Earning Guidance for Fiscal Year 2024

Price target increased by 12% to US$17.33

Consensus EPS estimates fall by 52%, revenue upgraded

AngioDynamics, Inc. Provides Financial Guidance for the Fiscal Year 2024

Recent updates

CEO, President & Director recently bought US$67k worth of stock

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry

Price target decreased by 10.0% to US$13.50

Insufficient new directors

AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024

Angiodynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc

AngioDynamics, Inc. to Report Q3, 2024 Results on Apr 04, 2024

Angiodynamics, Inc. Announces Board Changes

Angiodynamics Announces FDA 510(K) Clearance of Auryon Xl Radial Access Catheter to Treat Peripheral Arterial Disease

AngioDynamics: Restructuring Initiative May Not Go Far Enough

AngioDynamics, Inc. Announces Manufacturing Operations Restructuring

David D. Helsel to Leave AngioDynamics, Inc. as Senior Vice President of Global Operations and R&D, Effective January 12, 2024

AngioDynamics, Inc. to Report Q2, 2024 Results on Jan 05, 2024

AngioDynamics, Inc. Completes Patient Enrollment in Apex-Av Study Assessing Alphavac F1885 System in Treatment of Pulmonary Embolism

AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Angiodynamics, Inc. Provides Earning Guidance for Fiscal Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

AngioDynamics, Inc., Annual General Meeting, Nov 14, 2023

Price target increased by 12% to US$17.33

AngioDynamics, Inc. to Report Q1, 2024 Results on Oct 04, 2023

AngioDynamics, Inc. Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation

Angiodynamics, Inc. Completes Enrollment for Preserve Clinical Study

CEO, President & Director exercised options and sold US$102k worth of stock

AngioDynamics, Inc. Announces Addition of Lorinda Burgess to Board of Directors

Consensus EPS estimates fall by 52%, revenue upgraded

AngioDynamics, Inc. Provides Financial Guidance for the Fiscal Year 2024

No longer forecast to breakeven

Full year 2023 earnings: EPS misses analyst expectations

AngioDynamics, Inc. to Report Q4, 2023 Results on Jul 12, 2023

New minor risk - Profitability

Merit Medical Systems, Inc. (NasdaqGS:MMSI) acquired Dialysis Product Portfolio and BioSentry Product of AngioDynamics, Inc. (NasdaqGS:ANGO) for $100 million.

Forecast to breakeven in 2026

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt

Price target decreased by 22% to US$20.00

Key Executive recently sold US$60k worth of stock

Price target decreased to US$24.00

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

AngioDynamics, Inc. Reaffirms Revenue Guidance for Fiscal 2023

AngioDynamics, Inc. to Report Q2, 2023 Results on Jan 05, 2023

Price target decreased to US$26.50

Insufficient new directors

AngioDynamics, Inc. Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F1885 PE System in Treatment of Pulmonary Embolism

CEO, President & Director recently bought US$150k worth of stock

First quarter 2023 earnings: EPS and revenues miss analyst expectations

AngioDynamics, Inc. Reaffirms Earnings Guidance for the Year 2023

AngioDynamics Non-GAAP EPS of -$0.06 misses by $0.04, revenue of $81.5M misses by $1.93M, reaffirms FY guidance

AngioDynamics: Lack Of Upside Capture Remains, Continue To Hold

AngioDynamics, Inc., Annual General Meeting, Nov 03, 2022

AngioDynamics, Inc. to Report Q1, 2023 Results on Oct 06, 2022

Is AngioDynamics (NASDAQ:ANGO) Using Debt In A Risky Way?

Key Executive recently sold US$112k worth of stock

Executive VP & CFO exercised options and sold US$67k worth of stock

Consensus forecasts updated

Price target decreased to US$31.00

Forecast to breakeven in 2025

AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2023

AngioDynamics Non-GAAP EPS of $0.01 in-line, revenue of $87M beats by $4.09M

CEO, President & Director exercised options and sold US$176k worth of stock

AngioDynamics, Inc. to Report Q4, 2022 Results on Jul 12, 2022

Key Executive recently sold US$79k worth of stock

Price target increased to US$36.00

Independent Non-Executive Chairman exercised options to buy US$136k worth of stock.

Insufficient new directors

Independent Non-Executive Chairman exercised options to buy US$140k worth of stock.

Independent Director notifies of intention to sell stock

Consensus forecasts updated

Price target increased to US$36.00